Literature DB >> 16330908

Are myocardial fibrosis and diastolic dysfunction reversible in hypertensive heart disease?

Karl T Weber1.   

Abstract

Diastolic dysfunction is an important factor contributing to the appearance of symptomatic heart failure, particularly among elderly women with arterial hypertension. In hypertensive heart disease, the presence of cardiac fibrosis is an important determinant of abnormal myocardial stiffness that contributes to diastolic dysfunction. Recent studies indicate the feasibility of a pharmacology-based regression of fibrosis and improvement in diastolic stiffness.

Entities:  

Mesh：

Year:  2005        PMID： 16330908     DOI： 10.1111/j.1527-5299.2005.04479.x

Source DB:  PubMed          Journal:  Congest Heart Fail        ISSN： 1527-5299


  12 in total

1.  Role of the renin-angiotensin system in age-related sarcopenia and diastolic dysfunction.

Authors:  Christy S Carter; Leanne Groban
Journal:  Aging health       Date:  2008-02-01

Review 2.  Transient receptor potential (TRP) channels and cardiac fibrosis.

Authors:  Zhichao Yue; Yanhui Zhang; Jia Xie; Jianmin Jiang; Lixia Yue
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

3.  Sexual dimorphism in the fetal cardiac response to maternal nutrient restriction.

Authors:  Sribalasubashini Muralimanoharan; Cun Li; Ernesto S Nakayasu; Cameron P Casey; Thomas O Metz; Peter W Nathanielsz; Alina Maloyan
Journal:  J Mol Cell Cardiol       Date:  2017-06-19       Impact factor: 5.000

Review 4.  Recent Advances in Imaging of Hypertensive Heart Disease.

Authors:  Christopher L Schumann; Nicholas R Jaeger; Christopher M Kramer
Journal:  Curr Hypertens Rep       Date:  2019-01-14       Impact factor: 5.369

Review 5.  Imaging tools for assessment of myocardial fibrosis in humans: the need for greater detail.

Authors:  Summer Hassan; Carolyn J Barrett; David J Crossman
Journal:  Biophys Rev       Date:  2020-07-23

6.  A state of reversible compensated ventricular dysfunction precedes pathological remodelling in response to cardiomyocyte-specific activity of angiotensin II type-1 receptor in mice.

Authors:  Georgia A Frentzou; Mark J Drinkhill; Neil A Turner; Stephen G Ball; Justin F X Ainscough
Journal:  Dis Model Mech       Date:  2015-06-18       Impact factor: 5.758

7.  Leukocytic Toll-Like Receptor 2 Deficiency Preserves Cardiac Function And Reduces Fibrosis In Sustained Pressure Overload.

Authors:  Jiong-Wei Wang; Magda S C Fontes; Xiaoyuan Wang; Suet Yen Chong; Elise L Kessler; Ya-Nan Zhang; Judith J de Haan; Fatih Arslan; Saskia C A de Jager; Leo Timmers; Toon A B van Veen; Carolyn S P Lam; Dominique P V de Kleijn
Journal:  Sci Rep       Date:  2017-08-23       Impact factor: 4.379

Review 8.  Human pluripotent stem cell-based cardiovascular disease modeling and drug discovery.

Authors:  Ge Liu; Zhun Liu; Nan Cao
Journal:  Pflugers Arch       Date:  2021-03-08       Impact factor: 3.657

9.  Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis.

Authors:  Evren Caglayan; Bradley Stauber; Alan R Collins; Christopher J Lyon; Fen Yin; Joey Liu; Stephan Rosenkranz; Erland Erdmann; Leif E Peterson; Robert S Ross; Rajendra K Tangirala; Willa A Hsueh
Journal:  Diabetes       Date:  2008-05-28       Impact factor: 9.461

10.  PPARδ activity in cardiovascular diseases: A potential pharmacological target.

Authors:  Angela Tesse; Ramaroson Andriantsitohaina; Thierry Ragot
Journal:  PPAR Res       Date:  2009-03-23       Impact factor: 4.964
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.